HSP90AA1 and pulmonary arterial hypertension: It was demonstrated that targeted inhibition of mitochondrial Hsp90 with Gamitrinib reversed pulmonary vascular remodeling and improved cardiac output in two PAH models without noticeable toxicity (Boucherat et al., 2018).